{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T23:06:56Z","timestamp":1773702416357,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1038\/s41375-024-02316-5","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T08:02:02Z","timestamp":1719302522000},"page":"2085-2086","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Is there really an accelerated phase of chronic myeloid leukaemia?"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-1676","authenticated-orcid":false,"given":"Robert Peter","family":"Gale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7131-0522","authenticated-orcid":false,"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1710-1794","authenticated-orcid":false,"given":"Jane F.","family":"Apperley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"key":"2316_CR1","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1200\/JCO.23.01689","volume":"42","author":"E Berman","year":"2024","unstructured":"Berman E, Shah NP, Deninger M, Altman JK, Amaya M, Begna K, et al. and the WHO: Why? J Clin Oncol. 2024;42:984\u20136.","journal-title":"J Clin Oncol"},{"key":"2316_CR2","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"2316_CR3","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384.","journal-title":"Leukemia"},{"key":"2316_CR4","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KC, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"2316_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","volume":"22","author":"NP Shah","year":"2024","unstructured":"Shah NP, Bhatia R, Altman JK, Amaya M, Begna KH, Berman E, et al. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22:43\u201369.","journal-title":"J Natl Compr Canc Netw"},{"key":"2316_CR6","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"2316_CR7","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1002\/ajh.27007","volume":"98","author":"HM Kantarjian","year":"2023","unstructured":"Kantarjian HM, Tefferi A. Classification of accelerated phase chronic myeloid leukemia in the era of the BCR::ABL1 tyrosine kinase inhibitors: A work in progress. Am J Hematol. 2023;98:1350\u20133.","journal-title":"Am J Hematol"},{"key":"2316_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/BF00320152","volume":"57","author":"LY Shih","year":"1988","unstructured":"Shih LY, Chiu WF, Dunn P, Liaw SJ. In vitro culture studies of blood and marrow cells in chronic myeloid leukemia at different phases of the disease. Blut. 1988;57:125\u201330.","journal-title":"Blut"},{"key":"2316_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1177\/030089168507100401","volume":"71","author":"PN Anklesaria","year":"1985","unstructured":"Anklesaria PN, Advani SH, Bhisey AN. Studies on granulocyte functions in patients with chronic myeloid leukemia. Tumori. 1985;71:317\u201323.","journal-title":"Tumori"},{"key":"2316_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1182\/blood.V73.1.117.117","volume":"73","author":"K Watari","year":"1989","unstructured":"Watari K, Asano S, Shirafuji N, Kodo H, Ozawa K, Takaku F, et al. Serum granulocyte colony-stimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immunoassay. Blood. 1989;73:117\u201322.","journal-title":"Blood"},{"key":"2316_CR11","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1073\/pnas.0510423103","volume":"103","author":"JP Radich","year":"2006","unstructured":"Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA. 2006;103:2794\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2316_CR12","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1182\/blood.V32.3.445.445","volume":"33","author":"A Karanas","year":"1968","unstructured":"Karanas A, Silver RT. Characteristics of the terminal phase of chronic granulocytic leukemia. Blood. 1968;33:445\u201359.","journal-title":"Blood"},{"key":"2316_CR13","unstructured":"Yang S, Zhang X, Gale RP, Jiang Q. Goodbye to accelerated phase of chronic myeloid leukaemia. Submitted."},{"key":"2316_CR14","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1038\/s41375-023-02028-2","volume":"37","author":"M Lauseker","year":"2023","unstructured":"Lauseker M, Hehlmann R, Hochhaus A, Sau\u00dfele S. Survival with chronic myeloid leukaemia after failing milestones. Leukemia. 2023;37:2231\u20136.","journal-title":"Leukemia"},{"key":"2316_CR15","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1038\/s41375-022-01681-3","volume":"36","author":"R Hehlmann","year":"2022","unstructured":"Hehlmann R, Lauseker M, Voskanyan A, Fabarius A, Haferlach C, Hochhaus A, et al. Impact of emerging ACA on survival in chronic myeloid leukemia (CML). Leukemia. 2022;36:2544\u201347.","journal-title":"Leukemia"},{"key":"2316_CR16","first-page":"313","volume":"36","author":"M Sakurai","year":"1976","unstructured":"Sakurai M, Hayata I, Sandberg AA. Prognostic value of chromosomal findings in Ph1-positive chronic myelocytic leukemia. Cancer Res. 1976;36:313\u20138.","journal-title":"Cancer Res"},{"key":"2316_CR17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1667\/RR2892.1","volume":"179","author":"WL Hsu","year":"2013","unstructured":"Hsu WL, Preston DL, Soda M, Sugiyama H, Funamoto S, Kodama K, et al. The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950\u20132001. Radiat Res. 2013;179:361\u201382.","journal-title":"Radiat Res"},{"key":"2316_CR18","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.blre.2022.101017","volume":"58","author":"RP Gale","year":"2023","unstructured":"Gale RP. Radiation and leukaemia: Which leukaemias and what doses? Blood Rev. 2023;58:1010\u201317. https:\/\/doi.org\/10.1016\/j.blre.2022.101017","journal-title":"Blood Rev"},{"key":"2316_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1159\/000204364","volume":"90","author":"I Aurer","year":"1993","unstructured":"Aurer I, Juhbashi T, Sekine I, Tomonaga M, Gale RP. Analysis of BCR\/ABL abnormalities in mRNA from 20-year-old paraffin-embedded tissue for BCR\/ABL rearrangement by polymerase chain reaction. Acta Haematol. 1993;90:5\u20137.","journal-title":"Acta Haematol"},{"key":"2316_CR20","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/1097-0142(196503)18:3<369::AID-CNCR2820180313>3.0.CO;2-M","volume":"18","author":"GW Morrow Jr","year":"1965","unstructured":"Morrow GW Jr, Pease CL, Stroebel CF, Bennett WA. Terminal phase of chronic myelogenous leukemia. Cancer 1965;18:369.","journal-title":"Cancer"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02316-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02316-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02316-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T11:03:16Z","timestamp":1727434996000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02316-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2316"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02316-5","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]},"assertion":[{"value":"4 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RPG is a consultant to Antengene Biotech LLC; Medical Director, FFF Enterprises Inc.; Speaker for Janssen Pharma and Hengrui Pharma; Board of Directors: Russian Foundation for Cancer Research Support; and Scientific Advisory Board: StemRad Ltd. JFA Advisory Boards Novartis, Terns, Ascentage; Speaker: Novartis, Incyte, Paladin. Research funding: Pfier, Incyte. AH received research support by Novartis, BMS, Incyte, Pfizer and Enliven Pharma. RPG and AH are Editors-in-Chief of <i>LEUKEMIA<\/i>.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}